Dr. Reddy’s Laboratories (NYSE:RDY) Hits New 52-Week Low – Should You Sell?

Dr. Reddy’s Laboratories Limited (NYSE:RDY)’s share price reached a new 52-week low on Wednesday . The stock traded as low as $13.22 and last traded at $13.20, with a volume of 115167 shares changing hands. The stock had previously closed at $13.56.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. Finally, Barclays decreased their price objective on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Stock Performance

The stock’s 50-day moving average price is $14.65 and its 200 day moving average price is $15.22. The firm has a market cap of $11.13 billion, a P/E ratio of 21.23 and a beta of 0.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, equities analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 43.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock valued at $36,000 after buying an additional 137 shares during the last quarter. Van ECK Associates Corp lifted its stake in Dr. Reddy’s Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock valued at $64,000 after acquiring an additional 322 shares during the last quarter. Lifestyle Asset Management Inc. grew its position in shares of Dr. Reddy’s Laboratories by 3.2% in the 3rd quarter. Lifestyle Asset Management Inc. now owns 13,689 shares of the company’s stock valued at $1,088,000 after acquiring an additional 422 shares during the period. Natixis Advisors LLC increased its stake in shares of Dr. Reddy’s Laboratories by 7.2% during the 3rd quarter. Natixis Advisors LLC now owns 10,937 shares of the company’s stock worth $869,000 after purchasing an additional 735 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in shares of Dr. Reddy’s Laboratories in the 3rd quarter valued at about $60,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.